Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3830276 | 0.76 | TSHR (0.50) | TSHR | |
| SCHEMBL2784984 | 0.70 | TSHR (0.43) | TSHR | |
| SCHEMBL22443062 | 0.67 | TSHR (0.46) | TSHR | |
| SCHEMBL17072311 | 0.64 | — | — | |
| SCHEMBL15349735 | 0.64 | — | — | |
| SCHEMBL760206 | 0.64 | — | — | |
| SCHEMBL28552922 | 0.64 | TSHR (0.37) | TSHR | |
| SCHEMBL934921 | 0.64 | — | — | |
| SCHEMBL6543364 | 0.62 | — | — | |
| SCHEMBL3812042 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2049543-B1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | CALLAGHAN INNOVATION RES LTD (NZ) | 2014-11-05 | — | — | EP | claimed |
| US-8383636-B2 | Acyclic amine inhibitors of 5-methytioadenosine phosphorylase and nucleosidase | INDUSTRIAL RESEARCH LIMITED (NZ) | 2013-02-26 | — | — | US | claimed |
| EP-2395005-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | Industrial Research Limited (NZ) | 2011-12-14 | — | — | EP | claimed |
| EP-2348854-A2 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING QUORUM SENSING | Albert Einstein College Of Medecine Of Yeshiva University (US) | 2011-08-03 | — | — | EP | claimed |
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | BIOCRYST PHARMACEUTICALS, INC. | 2011-06-02 | — | — | US | claimed |
| US-20110046167-A1 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2011-02-24 | — | — | US | claimed |
| WO-2010033236-A2 | METHODS AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING QUORUM SENSING | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2010-03-25 | — | — | WO | claimed |
| WO-2008030119-A9 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-09-24 | — | — | WO | claimed |
| EP-2057165-A1 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-05-13 | — | — | EP | claimed |
| EP-2049543-A1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-04-22 | — | — | EP | claimed |
| WO-2008030118-A1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-03-13 | — | — | WO | claimed |
| WO-2008030119-A1 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-03-13 | — | — | WO | claimed |
| US-10918641-B2 | Use of MTAP inhibitors for the treatment of lung disease | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2021-02-16 | — | — | US | disclosed |
| US-20180353511-A1 | Use of MTAP Inhibitors for the Treatment of Lung Disease | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2018-12-13 | — | — | US | disclosed |
| US-9957272-B2 | 3-hydroxypyrrolidine inhibitors of 5′-methylthioadenosine phosphorylase and nucleosidase | VICTORIA LINK LIMITED (NZ) | 2018-05-01 | — | — | US | disclosed |
| US-20170166573-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | VICTORIA LINK LIMITED (NZ) | 2017-06-15 | — | — | US | disclosed |
| EP-2057165-A1 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-05-13 | — | — | EP | disclosed |
| EP-2049543-A1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008030118-A1 | ACYCLIC AMINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030119-A1 | ACYCLIC AMINE INHIBITORS OF NUCLEOSIDE PHOSPHORYLASES AND HYDROLASES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180353511-A1 | Use of MTAP Inhibitors for the Treatment of Lung Disease | MTAP, TYMP, TPMT | TSHR 4473/4885 |
| US-20110130412-A1 | Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases | PNP, TYMP, NTPCR | TSHR 3078/4885 |
| US-20170166573-A1 | 3-HYDROXYPYRROLIDINE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | TYMP, MTAP, PNP | TSHR 3902/4885 |
| US-20110046167-A1 | ACYCLIC AMINE INHIBITORS OF 5-METHYTIOADENOSINE PHOSPHORYLASE AND NUCLEOSIDASE | MTAP, PNP, TYMP | TSHR 3081/4885 |
| US-10918641-B2 | Use of MTAP inhibitors for the treatment of lung disease | MTAP, TYMP, TPMT | TSHR 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.